CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Ponatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02478164
NCT02478164Phase 2Completed
CompareCT.gov

Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Dana-Farber Cancer Institute·interventional·Posted Jun 23, 2015·Updated Jul 24, 2018

In Brief

A Phase 2 clinical trial evaluating Ponatinib for Glioblastoma. Completed, enrolled 17 participants across 2 sites.

Detailed Summary

This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 23, 2015
Enrollment StartJul 13, 2015
Primary CompletionJul 8, 2017
Study CompletionMay 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.0 years ago

Interventions

Ponatinibdrug